Plastics In Personalized Drug Delivery Systems Market (2026 - 2033)

Plastics In Personalized Drug Delivery Systems Market Summary

The plastics in personalized drug delivery systems market size was valued at USD 2.1 billion in 2025 and is projected to grow from USD 2.3 billion in 2026 to USD 5.4 billion by 2033, at a CAGR of 12.7% from 2026 to 2033. Asia Pacific dominated the plastics in personalized drug delivery systems market with the largest revenue share of 40.5% in 2025. Increasing adoption of smart and biodegradable polymers across targeted drug delivery, controlled-release formulations, implants, and advanced delivery devices is driving market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Rising demand for personalized therapies further supports expansion through advances in polymer chemistry, stimulus-responsive materials, nanotechnology, and microneedle technologies that improve drug stability, release precision, biocompatibility, and patient compliance.Continuous innovations in polymer chemistry are enabling the development of highly functional, biocompatible, and responsive plastics for more efficient and targeted drug delivery. These materials enhance drug stability, controlled release, and patient compliance, driving market growth.

To learn more about this report, Download Free Sample Report

The plastics in personalized drug delivery systems industry is witnessing a significant shift towards smart polymer integration, enabling precise, time-controlled drug release mechanisms. These polymers, designed to respond to physiological stimuli such as pH, temperature, and enzymatic activity, are revolutionizing patient-centric treatment approaches. The development of biodegradable and bioresorbable plastic materials is particularly gaining momentum, as they eliminate the need for device retrieval post-administration. This trend aligns with the broader healthcare transition towards precision medicine, ensuring optimized therapeutic outcomes and reducing systemic side effects. Additionally, the convergence of nanotechnology and polymer science is fostering innovations such as polymeric nanoparticles and microneedle patches, further strengthening the role of plastics in next-generation personalized drug delivery systems.

Market Dynamics

Demand for plastics in the personalized drug delivery systems market is being shaped by the shift toward biocompatible, responsive, and biodegradable polymers that support targeted release, sustained dosing, and better patient compliance. End-use intensity is highest in pharmaceutical delivery and implantable systems, where polymeric nanocarriers, microneedle patches, and degradable matrices are being used to improve stability and therapeutic precision. Asia Pacific remains the main demand center, while North America and Europe contribute high-value demand through R&D, regulation, and sustainability-led adoption. Commercial activity is concentrated among qualified material suppliers, pharma partners, and contract developers that can commercialize validated formulations.

Analyst Perspective

The market for Plastics in Personalized Drug Delivery Systems is projected to see significant growth, propelled by the rising use of patient-specific treatments, biologics, and precision medicine. There is a growing demand for high-performance medical-grade polymers that facilitate intricate drug delivery systems, such as wearable injectors, autoinjectors, implantable devices, inhalers, and microfluidic apparatus, where factors like dimensional accuracy, biocompatibility, chemical resilience, and compatibility with sterilization processes are essential. Innovations in materials are increasingly aimed at improving drug compatibility, supporting miniaturization, and advancing manufacturing methods like micro-molding and additive manufacturing. While strict regulatory demands, comprehensive validation requirements, and lengthy material qualification processes will continue to pose challenges, these conditions are likely to benefit established polymer suppliers who possess strong regulatory knowledge and consistent quality standards.

Type Insights & Trends

Based on type, the polylactic acid (PLA) plastics in the personalized drug delivery systems segment led the market with the largest revenue share of 27.4% in 2025. This growth can be attributed to the rising regulatory emphasis on sustainable medical materials. As a biodegradable and bioabsorbable polymer, PLA aligns with global sustainability goals, addressing both environmental concerns and patient safety.

The increasing need for single-use, biocompatible drug carriers-especially in applications such as injectable nanoparticles, microspheres, and transdermal patches-is accelerating PLA’s integration into advanced drug delivery mechanisms. Furthermore, leading pharmaceutical firms and medical device manufacturers are investing in PLA-based solutions to comply with stringent EU MDR (Medical Device Regulation) and FDA biocompatibility standards, reinforcing its market growth.

The rising prevalence of chronic diseases, such as diabetes, cancer, and autoimmune disorders, is driving the demand for Poly(lactic-co-glycolic acid) (PLGA)-based drug delivery systems that enable long-acting injectable (LAI) therapies. PLGA’s excellent biodegradability, controlled drug-release properties, and regulatory approval by the FDA make it the preferred polymer for formulating sustained-release drugs, protein therapeutics, and vaccine carriers.

The ongoing expansion of mRNA-based vaccines and monoclonal antibody therapies has further positioned PLGA as a critical material for precise, controlled, and patient-friendly drug administration. With major pharmaceutical players intensifying their focus on reducing dosing frequency and improving treatment adherence, PLGA-based formulations continue to gain momentum in next-generation personalized drug delivery.

End Use Insights & Trends

Based on end-use, the pharmaceuticals & drug delivery segment led the market with the largest revenue share of 38.5% in 2025. This is attributable to the growing shift towards nano-enabled drug delivery systems. Advances in polymeric nanocarriers, including liposomes, dendrimers, and polymeric micelles, are transforming drug bioavailability, solubility, and cellular uptake.

Leading biotech firms are actively investing in smart polymeric matrices, leveraging plastics to improve drug encapsulation, site-specific release, and patient compliance. Additionally, strategic partnerships between pharma giants and material science companies are accelerating the commercialization of plastic-based nano-formulations, positioning this segment for rapid expansion amid the demand for precision medicine and biologics.

To learn more about this report, Download Free Sample Report

The increasing adoption of biodegradable polymer-based implants for localized and sustained drug delivery is a major growth driver within the Medical Devices & Implants segment. Advanced polymer-based implants-such as drug-eluting stents, intraocular lenses, and orthopedic scaffolds-are gaining traction due to their ability to enhance therapeutic efficacy while eliminating the need for secondary surgical removal.

The integration of 3D printing technologies with polymeric biomaterials is further enabling the customization of implantable drug delivery systems tailored to individual patient needs. As regulatory bodies push for safer, more effective implant materials, medical device manufacturers are increasingly shifting towards biodegradable polymer solutions that provide controlled, localized treatment while improving patient outcomes.

Regional Insights & Trends

Asia Pacific dominated the plastics in personalized drug delivery systems market with the largest revenue share of 40.5% in 2025. Asia Pacific is emerging as a high-growth region for polymer-based personalized drug delivery, driven by the increasing adoption of precision medicine and advancements in polymer engineering.

To learn more about this report, Download Free Sample Report

The plastics in personalized drug delivery systems market in China accounted for the largest market revenue share in the Asia Pacific in 2025. The region's rapidly evolving pharmaceutical and biotech sectors, particularly in India, Japan, and South Korea, are fostering innovations in smart, stimuli-responsive polymeric drug carriers for targeted and controlled drug release applications. The rising burden of chronic diseases, an aging population, and government-backed healthcare digitization programs have fueled investments in next-generation polymeric drug delivery technologies, including self-regulating polymeric implants and microfluidic polymer drug dispensers.

North America Plastics In Personalized Drug Delivery Systems Market Trends

North America is experiencing a significant rise in biopharmaceutical research and polymer-based drug delivery innovations, driven by strong funding in precision medicine and advanced material sciences. The region's well-established healthcare infrastructure, coupled with high R&D investments from pharmaceutical giants such as Pfizer, Moderna, and Johnson & Johnson, is fueling the adoption of biodegradable and bioresponsive plastics in personalized drug delivery.

U.S. Plastics In Personalized Drug Delivery Systems Market Trends

In the U.S., the regulatory landscape is a key driver accelerating the adoption of plastics in personalized drug delivery systems, particularly due to the FDA’s progressive stance on innovative polymer-based drug carriers. The expedited approval pathways for novel drug delivery technologies, such as 3D-printed polymer-based implants and biodegradable polymeric nanoparticles, have encouraged pharmaceutical companies to explore cutting-edge polymer formulations. The presence of leading biotech startups and material science companies specializing in biodegradable polymers for sustained and targeted drug release is further fueling market expansion.

Europe Plastics In Personalized Drug Delivery Systems Market Trends

Europe is witnessing a strong push toward sustainability in healthcare, which is significantly driving the adoption of bio-based and biodegradable plastics in personalized drug delivery systems. With the EU Medical Device Regulation (MDR) tightening safety and environmental standards, pharmaceutical and medical device manufacturers are investing in biocompatible, eco-friendly polymer materials such as polyhydroxyalkanoates (PHAs) and polylactic acid (PLA) for drug encapsulation and controlled-release applications. The region’s strong biotechnology ecosystem, particularly in Germany, France, and the Netherlands, is fostering advancements in polymeric nanomedicine and biodegradable polymeric scaffolds for targeted therapies.

China plastics In personalized drug delivery systems market is expected to grow during the forecast period. China is actively driving the adoption of polymer-based personalized drug delivery solutions through strategic government initiatives, local biotech advancements, and regulatory reforms supporting high-tech pharmaceutical manufacturing. The Made in China 2025 policy has prioritized biopolymer research and innovation, encouraging the development of biodegradable, bioresorbable, and intelligent polymer materials for long-acting injectables, targeted therapies, and transdermal drug patches. With the China National Medical Products Administration (NMPA) accelerating approvals for novel polymer-based drug delivery systems, domestic pharmaceutical giants and biotech startups are rapidly investing in polymeric nanocarriers, smart hydrogel-based drug release systems, and personalized polymer implants.

Key Plastics In Personalized Drug Delivery Systems Company Insights

The plastics in personalized drug delivery systems market is highly competitive, with several key players dominating the landscape. Major companies include BASF SE; Evonik Industries; Corbion; Eastman Chemical Company; DuPont de Nemours, Inc.; DSM; Lubrizol Corporation; Arkema; Celanese Corporation; and Avient Corporation. The market is characterized by a competitive landscape with several key players driving innovation and market growth. Major companies in this sector are investing heavily in research and development to enhance the performance, cost-effectiveness, and sustainability of their types.

Key Plastics In Personalized Drug Delivery Systems Companies

The following key companies have been profiled for this study on the plastics in personalized drug delivery systems market.

• BASF SE

• Evonik Industries

• Corbion

• Eastman Chemical Company

• DuPont de Nemours, Inc.

• DSM

• Lubrizol Corporation

• Arkema

• Celanese Corporation

• Avient Corporation

Recent Developments

• In November 2024, Avantium and SCGC strengthened their partnership to advance the development of PLGA polyester, a biodegradable and recyclable material. They signed a multi-year agreement to pilot PLGA production using Avantium's Volta Technology, which converts CO2 into glycolic acid, a key component of PLGA.

• In July 2023, CD Bioparticles, a company experienced in pharmaceuticals and life sciences, recently launched a new line of PLGA-based drug delivery systems. These systems are designed for both in vitro and in vivo applications and include biocompatible and biodegradable PLGA nanoparticles with various surface modifications. These nanoparticles can transport different types of drugs, protect them from degradation, and enhance interaction with biological materials. The new product line includes Streptavidin Coated PLGA Nanoparticles, Functionalized PLGA Nanoparticles, and Functionalized Fluorescent Magnetic PLGA Nanoparticles.

Global Plastics In Personalized Drug Delivery Systems Market Report Segmentation

This report forecasts volume & revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented plastics in personalized drug delivery systems market report based on type, end use, and region:

To learn more about this report, Download Free Sample Report

• Type Outlook (Volume, Kilotons; Revenue, USD Million, 2021 - 2033)

  • Polylactic Acid (PLA)

  • Poly(lactic-co-glycolic acid) (PLGA)

  • Polyethylene Glycol (PEG)

  • Polyurethane (PU)

  • Polyether Ether Ketone (PEEK)

  • Others

• End Use Outlook (Volume, Kilotons; Revenue, USD Million, 2021 - 2033)

  • Pharmaceuticals & Drug Delivery

  • Medical Devices & Implants

  • Contract Manufacturing & Drug Formulation Services

  • Healthcare & Clinics

  • Others

• Regional Outlook (Volume, Kilotons; Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

  • Central & South America

    • Brazil

    • Argentina

  • Middle East & Africa

    • Saudi Arabia

    • South Africa

    • UAE

Research Methodology

The plastics in personalized drug delivery systems Market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each plastics in personalized drug delivery systems Market segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations